SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001493152-24-050399
Filing Date
2024-12-17
Accepted
2024-12-17 16:05:22
Documents
7
Period of Report
2024-12-17

Document Format Files

Seq Description Document Type Size
1 formdef14a.htm DEF 14A 820893
2 formdef14a_001.jpg GRAPHIC 5372
3 formdef14a_002.jpg GRAPHIC 46311
4 formdef14a_003.jpg GRAPHIC 251317
5 formdef14a_004.jpg GRAPHIC 241801
6 formdef14a_005.jpg GRAPHIC 237730
7 formdef14a_006.jpg GRAPHIC 178104
  Complete submission text file 0001493152-24-050399.txt   2145747
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: DEF 14A | Act: 34 | File No.: 001-40101 | Film No.: 241555654
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)